DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

Information source: Hawler Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Venous Thromboembolic Diseases

Intervention: Bemiparin (Drug); Enoxaparin (Drug)

Phase: N/A

Status: Completed

Sponsored by: Hawler Medical University

Official(s) and/or principal investigator(s):
Shahla K. Alalaf, Ass.Prof, Principal Investigator, Affiliation: Hawler Medical University
Rojan K. Jawad, High Diploma, Study Chair, Affiliation: Hawler Medical University
Parez R. Muhammad, High Diploma, Study Chair, Affiliation: Hawler Medical University
Mahabad S. Ali, High Diploma, Study Chair, Affiliation: Hawler ministry of Health, Directorate of Health
Namir G. Al Tawil, Professor, Study Director, Affiliation: Hawler Medical University


The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

Clinical Details

Official title: Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Venous thromboembolism

Secondary outcome: adverse effects

Detailed description: Venous thromboembolism (VTE) is the leading cause of maternal mortality and morbidity in the developed and developing world. Pulmonary embolism and deep vein thrombosis are the two components of a single disease called deep vein thrombosis (DVT). Pregnancy associated with an average 5 to 10 fold increase in the risk of VTE compared with non-pregnant women. The highest incidence occurring during the post partum period. There are many researches done a broad on the effect of LMWH to decrease the incidence of VTE after Caesarean section using the two LMWH (Enoxaparin and Bemiparin) alone but not in one research comparing both of them alone and both together against a control group. Also according to our knowledge there are no published literature on thromboprophylaxis after vaginal delivery


Minimum age: 15 Years. Maximum age: 48 Years. Gender(s): Female.


Inclusion Criteria:

- Presence of risk factors for venous thromboembolism

- Any parity

- Mode of delivery: vaginal, Emergency and Elective Caesarean section

- No any contraindications for Heparin

Exclusion Criteria:

- Active antenatal or postpartum vaginal bleeding.

- Placenta previa

- Thrombocytopenia

- Sever renal or liver diseases

- Uncontrolled sever hypertension

- Any patient who is already on Heparin during pregnancy

Locations and Contacts

Hawler medical university, Erbil city, Kurdistan region 383-65, Iraq

Hawler medical university, Erbil, Kurdistan region 383-65, Iraq

Additional Information

Starting date: May 2012
Last updated: March 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017